Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery

Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery to Reduce Intraoperative and Postoperative Blood Loss: A Randomized Clinical Trial.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03148574

Enrollment

240

Registered

2017-05-11

Start date

2017-07-02

Completion date

2019-12-15

Last updated

2021-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Partum Hemorrhage

Brief summary

Bleeding is still the major cause of mortality and morbidity in postpartum period. World health organization has reported 585000 deaths for pregnancy each year. Twenty five percent of cases die from post-partum bleeding. Mean amount of blood lost is 500 ml during normal vaginal delivery, 1000 ml in cesarean section, and 3500 ml during cesarean section with emergency hysterectomy

Interventions

DRUGMisoprostol

intrauterine tablets

DRUGOxytocin

intravenous

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

1-Uncomplicated pregnancy, 2-Had no hypersensitivity or contraindications to prostaglandins. 3-Had no history of coagulopathy. 4-Accepting to participate in the study.

Exclusion criteria

\\1-women with anemia (Haemoglobin \<8 gram ). 2 placental abnormality (e.g placenta previa,placenta abruption ) 3. History of complications at previous pregnancy especially postpartum hemorrhage. 4- Maternal hypertension , current or previous history of heart disease ,liver ,Renal disorders or known coagulopathy

Design outcomes

Primary

Measure	Time frame
amount of intraoperative blood loss	30 minutes

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026